Form 8-K - Current report:
SEC Accession No. 0001493152-24-042315
Filing Date
2024-10-24
Accepted
2024-10-24 08:00:33
Documents
17
Period of Report
2024-10-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37005
2 ex99-1.htm EX-99.1 17502
3 ex99-1_001.jpg GRAPHIC 22062
4 ex99-1_002.jpg GRAPHIC 31405
5 ex99-1_003.jpg GRAPHIC 7218
  Complete submission text file 0001493152-24-042315.txt   320390

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE awh-20241024.xsd EX-101.SCH 3012
7 XBRL LABEL FILE awh-20241024_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE awh-20241024_pre.xml EX-101.PRE 24164
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3831
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 241390752
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)